CytomX Therapeutics (CTMX) Competitors $3.28 -0.02 (-0.61%) Closing price 04:00 PM EasternExtended Trading$3.26 -0.02 (-0.61%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CTMX vs. DYN, VERA, SRPT, APGE, NTLA, HROW, AUPH, IMCR, EWTX, and TWSTShould you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include Dyne Therapeutics (DYN), Vera Therapeutics (VERA), Sarepta Therapeutics (SRPT), Apogee Therapeutics (APGE), Intellia Therapeutics (NTLA), Harrow (HROW), Aurinia Pharmaceuticals (AUPH), Immunocore (IMCR), Edgewise Therapeutics (EWTX), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry. CytomX Therapeutics vs. Its Competitors Dyne Therapeutics Vera Therapeutics Sarepta Therapeutics Apogee Therapeutics Intellia Therapeutics Harrow Aurinia Pharmaceuticals Immunocore Edgewise Therapeutics Twist Bioscience Dyne Therapeutics (NASDAQ:DYN) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership. Do institutionals & insiders have more ownership in DYN or CTMX? 96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 14.1% of Dyne Therapeutics shares are held by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to DYN or CTMX? In the previous week, Dyne Therapeutics had 6 more articles in the media than CytomX Therapeutics. MarketBeat recorded 9 mentions for Dyne Therapeutics and 3 mentions for CytomX Therapeutics. Dyne Therapeutics' average media sentiment score of 0.56 beat CytomX Therapeutics' score of 0.19 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, DYN or CTMX? Dyne Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.27, indicating that its stock price is 127% more volatile than the S&P 500. Do analysts rate DYN or CTMX? Dyne Therapeutics presently has a consensus price target of $34.07, suggesting a potential upside of 169.30%. CytomX Therapeutics has a consensus price target of $5.42, suggesting a potential upside of 65.14%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Dyne Therapeutics is more favorable than CytomX Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyne Therapeutics 1 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 3 Strong Buy rating(s) 2.94CytomX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Which has higher valuation and earnings, DYN or CTMX? CytomX Therapeutics has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyne TherapeuticsN/AN/A-$317.42M-$3.86-3.28CytomX Therapeutics$138.10M3.92$31.87M$0.565.86 Is DYN or CTMX more profitable? CytomX Therapeutics has a net margin of 34.04% compared to Dyne Therapeutics' net margin of 0.00%. CytomX Therapeutics' return on equity of 158.70% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dyne TherapeuticsN/A -64.12% -56.75% CytomX Therapeutics 34.04%158.70%36.04% SummaryDyne Therapeutics and CytomX Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTMX vs. The Competition Export to ExcelMetricCytomX TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$540.91M$3.35B$6.10B$10.62BDividend YieldN/A2.28%5.64%4.69%P/E Ratio5.8622.1685.6627.13Price / Sales3.92265.75527.82206.05Price / Cash9.1246.3226.3031.10Price / Book-328.009.9612.926.67Net Income$31.87M-$52.42M$3.30B$276.23M7 Day Performance1.55%5.95%4.80%3.31%1 Month Performance43.86%11.59%8.11%10.76%1 Year Performance185.22%25.01%75.85%33.58% CytomX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTMXCytomX Therapeutics4.1397 of 5 stars$3.28-0.6%$5.42+65.1%+187.0%$544.21M$138.10M5.89170Gap UpDYNDyne Therapeutics3.4246 of 5 stars$12.37-5.9%$34.07+175.4%-59.9%$1.87BN/A-3.20100VERAVera Therapeutics2.8052 of 5 stars$28.90+2.5%$63.00+118.0%-26.2%$1.80BN/A-8.0740Positive NewsSRPTSarepta Therapeutics4.6561 of 5 stars$18.82+2.5%$39.32+108.9%-81.2%$1.79B$1.90B-21.631,372Gap UpAPGEApogee Therapeutics3.1459 of 5 stars$39.83+4.2%$92.63+132.6%-26.8%$1.76BN/A-9.6491Insider TradeNTLAIntellia Therapeutics4.5358 of 5 stars$16.92+3.7%$27.39+61.9%+11.0%$1.75B$57.88M-3.61600Analyst UpgradeGap UpHROWHarrow2.9759 of 5 stars$48.40+2.8%$67.83+40.2%-9.8%$1.74B$199.61M-193.60180Analyst RevisionAUPHAurinia Pharmaceuticals3.1558 of 5 stars$11.06-15.8%$13.00+17.5%+59.4%$1.73B$235.13M25.72300Gap UpHigh Trading VolumeIMCRImmunocore2.7182 of 5 stars$34.34+0.9%$56.89+65.7%+10.0%$1.71B$310.20M-85.85320Positive NewsEWTXEdgewise Therapeutics2.7913 of 5 stars$15.75-1.9%$38.83+146.6%-44.9%$1.69BN/A-10.1660TWSTTwist Bioscience3.7018 of 5 stars$27.00+0.3%$49.40+83.0%-28.3%$1.62B$312.97M-18.62990 Related Companies and Tools Related Companies Dyne Therapeutics Competitors Vera Therapeutics Competitors Sarepta Therapeutics Competitors Apogee Therapeutics Competitors Intellia Therapeutics Competitors Harrow Competitors Aurinia Pharmaceuticals Competitors Immunocore Competitors Edgewise Therapeutics Competitors Twist Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTMX) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredWarren Buffett’s #1 AI Stock is Not Even on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
